Could a cheaper, easier dose of immunotherapy work just as well?
NCT ID NCT07576725
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests whether giving a lower dose of the immunotherapy drug nivolumab less often can still control advanced cancers that have spread or can't be removed surgically. The goal is to make treatment more affordable and accessible worldwide. About 50 adults with various cancer types (like melanoma, lung, or kidney cancer) will receive the drug every 4 weeks instead of the standard schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Uganda Cancer Institute
Kampala, 3935, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.